China
Q&A: ZWC Partners’ Michael Yao
Michael Yao, a partner at ZWC Partners, discusses valuations, exit obstacles, and artificial intelligence in China, as well as the scope for applying China knowledge in Southeast Asia
Deal focus: Laiye leverages European connections
M&A helped Chinese artificial intelligence start-up Laiye develop its product and gain a foothold in Europe. With more than USD 160m in Series C funding, the company is aggressively targeting global expansion
China's VisionNav Robotics raises $80m
5Y Capital and Meituan, China’s leading online-to-offline services provider, have led a USD 80m Series C extension for VisionNav Robotics, a local manufacturer of driverless industrial vehicles.
Singapore mRNA vaccine developer raises $140m
RVAC Medicines, a Singapore-based company involved in developing messenger RNA (mRNA) vaccines for COVID-19, has closed a Series B round that takes its overall funding to USD 140m.
China delivery player Gogox files for Hong Kong IPO
Gogox, a last-mile logistics company formed through the merger of Hong Kong's GoGoVan and an affiliate of mainland China-based 58.com, has filed to list in Hong Kong
China RPA player Shadowbot raises $100m
Shadowbot, a China-based robotic process automation (RPA) service provider, has raised USD 100m in its Series C funding led by Goldman Sachs and an undisclosed corporate venture capital investor.
Profile: WestSummit Capital’s Raymond Yang
Raymond Yang’s rich entrepreneurial experience in China and the US led to the formation of WestSummit Capital. He continues to draw on this knowledge as technology ecosystems evolve
China digital CRO Elixir raises $52m
Elixir, a China-based clinical research organisation (CRO), has raised a USD 52m Series A round from Lyfe Capital, Chow Tai Fook Investment, and Sinovation Ventures.
China virotherapy specialist Binhui Biopharm raises $47m
Binhui Biopharm, a Chinese biotech firm specialising in oncolytic virus immune-oncology, has raised CNY 300m (USD 47m) in an extended Series B round led by Yangtze River Pharmaceutical Group.
China automation specialist Laiye raises $70m
Laiye Technology, a Chinese artificial intelligence (AI) start-up specialising in robotic process automation (RPA), has raised another extension - of USD 70m - to its Series C round. Hopu Investment took the lead.
China stem cell drug developer Baylx raises $47m
Baylx, a Beijing-based drug developer that utilises stem cell technology, has raised CNY 300m （USD 47m）across two rounds - a Series B and a Series B extension.
China consumer: Brand power vs traffic might
Private equity investment in China’s consumer sector has fluctuated over the past 18 months in line with the fortunes of portfolio companies. Applying TMT logic to brand building didn’t help
China game engine developer Cocos raises $50m
Cocos Technology, a China-based game engine developer, has raised USD 50m in Series B round from CCB Trust, GGV Capital, and voice and video communication platform Agora.
Sequoia targets USD 7.1bn for latest China vintage
Sequoia Capital has defied a difficult China fundraising environment to set a target of USD 7.1bn for its latest set of funds, which include an expansion vehicle in addition to the existing growth strategy.
1Q analysis: Monetising managers
Baring Asia and PAG underline the value of their management entities; exits slump amid uncertainty; BGH Capital, renminbi GPs shore up fundraising; investment fails to extend the late 2021 flourish
China metaverse infrastructure start-up raises $130m
Chinese metaverse start-up Xmov has raised USD 130m in Series B and Series C funding featuring SoftBank Vision Fund, Sequoia Capital China, Northern Light Capital, and Index Ventures.
Hosen closes $280m single asset continuation fund for Kilcoy
Hosen Capital, which makes investments in China’s consumer space, has closed a USD 280m single-asset continuation fund for Kilcoy Global Foods, a beef processing business it has owned since 2013.
China’s XVC raises $274m for third US dollar fund
Beijing-based venture capital firm XVC has raised USD 274m for its third US dollar-denominated vehicle. It brings overall assets under management to USD 1.2bn.
China's METiS Pharmaceuticals raises $150m
METiS Pharmaceuticals, a Hangzhou-based drug formulation company has raised USD 150m through two funding rounds led by PICC Capital and China Life PE.
China cybersecurity provider ThreatBook raises $47m
Beijing-based cybersecurity solutions provider ThreatBook has raised CNY 300m (USD 47m) in an extended Series E round led by CDH Investments, featuring existing investor Star Road Ventures.